Studies open for Enrollment
ABCSG 61 / TEODOR
Neoadjuvant TrEatment Optimization driven by ctDNA and endOcrine Responsiveness
A prospective, randomized, controlled, open-label multicenter phase II study investigating neoadjuvant endocrine therapy versus chemotherapy in HR-positive, HER2-negative, ctDNA-negative and endocrine responsive early and locally advanced breast cancer
ABCSG 65 / DEFINITIVE
Diagnostic HER2DX-guided treatment For patIeNts wIth early-stage HER2-posiTIVE breast cancer
An international, multicenter, prospective, two-arm, randomized, open-label Phase III study designed to demonstrate that personalized treatment decisions in HER2-positive early-stage breast cancer using the HER2DX® diagnostic test improve quality of life without compromising outcomes and survival rates.
ABCSG 66 / ADAPTela
ABCSG 66 / ADAPTela is a WSG-sponsored, adjuvant, open-label, interventional Phase III clinical trial for a high-risk HR-positive/HER2-negative early breast cancer patient population, comparing elacestrant with standard of care endocrine treatment (both arms with or without ribociclib). The genomic Oncotype DX® test is used to determine a specific genomic profile of patients, making it a personalized therapeutic approach to predict treatment benefits in HR-positive/HER2-negative early breast cancer.ABCSG 67N / CAROLEEN
A non-interventional study for ribociclib in combination with an aromatase inhibitor for adjuvant treatment in patients with HR+/HER2- early breast cancer at high risk of recurrence to evaluate real-world effectiveness, safety profile, patient compliance and quality of life
Share on